{"id":"dmx-200","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DMX-200 simultaneously inhibits vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2) signaling pathways. By targeting both pathways, it aims to normalize tumor vasculature and reduce pathological angiogenesis more effectively than single-target agents. This dual mechanism may improve drug delivery to tumors and reduce resistance development.","oneSentence":"DMX-200 is a dual VEGF and Ang2 inhibitor that blocks angiogenesis and vascular destabilization to reduce tumor blood supply and improve vascular function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:41.135Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diabetic kidney disease"},{"name":"Diabetic retinopathy"}]},"trialDetails":[{"nctId":"NCT05183646","phase":"PHASE3","title":"A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB","status":"RECRUITING","sponsor":"Dimerix Bioscience Pty Ltd","startDate":"2022-05-30","conditions":"FSGS","enrollment":286},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05122182","phase":"PHASE2","title":"Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19","status":"TERMINATED","sponsor":"University of Sydney","startDate":"2022-01-07","conditions":"COVID-19, SARS-CoV2 Infection","enrollment":49},{"nctId":"NCT03649152","phase":"PHASE2","title":"Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan","status":"COMPLETED","sponsor":"Dimerix Bioscience Pty Ltd","startDate":"2018-11-08","conditions":"Focal Segmental Glomerulosclerosis","enrollment":8},{"nctId":"NCT03627715","phase":"PHASE2","title":"Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan","status":"COMPLETED","sponsor":"Dimerix Bioscience Pty Ltd","startDate":"2018-11-06","conditions":"Diabetic Kidney Disease","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Repagermanium"],"phase":"phase_3","status":"active","brandName":"DMX-200","genericName":"DMX-200","companyName":"Dimerix Bioscience Pty Ltd","companyId":"dimerix-bioscience-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DMX-200 is a dual VEGF and Ang2 inhibitor that blocks angiogenesis and vascular destabilization to reduce tumor blood supply and improve vascular function. Used for Diabetic kidney disease, Diabetic retinopathy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}